Some fast-casual restaurant chains across the country are introducing new menu items specifically designed for customers taking GLP-1 medications, responding to the rapidly growing number of Americans using prescription weight-loss drugs. The offerings include protein-forward options such as lettuce-wrapped burger patties, high-protein smoothies containing up to 45 grams of protein, and portions of cut-up chicken.
The trend reflects broader shifts in how the food service industry is adapting to a patient population that experiences significantly reduced appetite while on medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). These drugs mimic the GLP-1 hormone, which regulates blood sugar and signals fullness to the brain.
What the Right Is Saying
Critics on the right have raised questions about whether the restaurant industry's adaptation represents appropriate market responsiveness or enables overreliance on pharmaceuticals for weight management. Some conservative commentators and healthcare policy analysts argue that rather than reshaping menus around medication side effects, greater emphasis should be placed on nutrition education and lifestyle interventions.
Fiscal conservatives have also noted concerns about the substantial costs of GLP-1 medications, which can exceed $1,000 per month without insurance coverage. The Mackinac Center for Public Policy and other free-market think tanks have argued that policy discussions around obesity should focus on expanding health savings accounts and flexible spending arrangements rather than expecting employers or restaurants to accommodate pharmaceutical treatments.
Some voices within the wellness community argue that the emergence of 'GLP-1 friendly' menus could normalize medication use among people who might otherwise pursue weight management through diet and exercise alone, though this view is not universally held across the political spectrum.
What the Left Is Saying
Proponents of expanded healthcare access say the restaurant industry's responsiveness demonstrates how the private sector can adapt to medical realities. Healthcare advocates note that GLP-1 medications have become an important tool in addressing obesity, a condition affecting more than 40% of American adults according to the Centers for Disease Control and Prevention.
Public health organizations including the Obesity Society have emphasized that obesity is a complex chronic disease influenced by genetic, environmental, and metabolic factors. Supporters argue that normalizing accommodations for patients on these medications reduces stigma and supports healthier lifestyle choices. The American Academy of Family Physicians has noted that comprehensive obesity treatment should include dietary support tailored to individual patient needs.
Consumer advocates also point out that making protein-rich options more accessible benefits not only GLP-1 users but anyone seeking higher-protein, lower-carb menu selections.
What the Numbers Show
GLP-1 medications have seen substantial growth in prescriptions: Novo Nordisk and Eli Lilly, the manufacturers of Ozempic, Wegovy, and Mounjaro, reported combined sales exceeding $20 billion in 2024 from their diabetes and weight-loss drug portfolios. Analysts project that the global market for these drugs could reach $100 billion annually by the end of the decade.
According to data from pharmacy benefit managers including Express Scripts and CVS Health's Caremark, GLP-1 prescriptions for weight loss purposes increased more than 300% between 2022 and 2024 among commercially insured populations. Approximately 15 million Americans were prescribed a GLP-1 medication in 2024, up from roughly 3 million in 2020.
The CDC reports that obesity affects approximately 42.4% of American adults, with related healthcare costs estimated at $173 billion annually. Studies have shown that patients on GLP-1 medications typically consume 20-30% fewer calories due to reduced appetite, making traditional restaurant portion sizes potentially excessive for this population.
The Bottom Line
The emergence of 'GLP-1 friendly' menu items represents a notable example of the food service industry adapting to medical trends rather than driving them. Whether this development warrants policy attention remains an open question among analysts, who note that restaurants have long offered customization options for various dietary preferences.
What to watch: Insurance coverage decisions regarding GLP-1 medications will likely influence demand for specialized menu offerings. Several states are considering legislation related to obesity treatment coverage under Medicaid expansion proposals, which could affect the patient population seeking these adapted restaurant options.